Fortune | March 15, 2022
“FDA must stop slow walking authorizing Novavax,” said Lawrence Gostin, director of the O’Neill Institute for National and Global Health Law at Georgetown University, in a tweet this week. “Every major regulatory agency has authorized it. It has good clinical data. A more traditional vaccine is easier to use & more acceptable to the public.”